Written by Katherine Tran Lupus is among the most perplexing autoimmune diseases. It can be debilitating when not regulated, with symptoms ranging from butterfly-shaped rashes across the face to fatigue,…
According to a story published in Healio, a recent study has concluded that a combination of standard treatment and belimumab produces better outcomes for patients of East Asian descent living with…
How do certain conditions contribute to mental health, depression, and anxiety? It's no secret that having a rare, chronic, or underserved condition can be isolating. But what are the actual…
1On July 27, 2022, global biopharmaceutical company GSK plc shared some exciting news via news release. The company’s therapy Benlysta (belimumab), designed for pediatric patients with lupus nephritis, is now…
Recently, an international group of pediatric rheumatologists and nephrologists met and created a consensus on a standard for a steroid-dosing regimen to treat childhood-onset systemic lupus erythematosus with proliferative lupus…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
In recent years, many studies have centered around the role of the gut – and the gut microbiota – on overall health. Some studies have identified how balancing imbalanced gut…
A recent study published in Advances in Rheumatology has uncovered 2 potential biomarkers which could be used to predict which lupus nephritis (LN) patients are at the highest risk of severe renal…
A recent article published in Physician's Weekly highlighted a study that compared four different treatment regimens for lupus nephritis. The options include low-dose cyclophosphamide (LDCyC), high-dose cyclophosphamide (HDCyC), rituximab, and…
Equillium Inc. has just announced that their most recent study in lupus nephritis (LN) has been published in the Journal of Clinical Investigation. This study is thanks to collaboration with the Accelerated Medicines…
Recently, Kezar Life Sciences Inc. ("Kezar") released interim data and preliminary results from part two of the Phase 2 MISSION clinical trial. According to BioPharma Journal, the results highlight the…
Aurinia Pharmaceuticals Inc. plans to release the updated results from their continuation study of AURORA 2. This clinical trial is evaluating LUPKYNIS, also known as voclosporin, as a treatment for…
Aurinia Pharmaceuticals has just announced that Otsuka Pharmaceutical Europe Ltd. (OPEL), their licensing partner, has just filed a Marketing Authorization Application for an investigative therapy for lupus nephritis (LN) called…
Early on in 2021, the FDA approved voclosporin as an add-on treatment for patients with lupus nephritis (LN), a frequent complication of lupus. Ultimately, this approval was a positive decision,…
In early May 2021, pharmaceutical company GlaxoSmithKline shared that its therapy Benlysta (belimumab) was approved by the European Commission (EC) for expanded use in adult patients with lupus nephritis…
Clinical trial data offers immense insight into a drug's safety, efficacy, and tolerability. But it can also share how combining two treatments can impact patient outcomes or whether a…
According to a story from Renal and Neurology News, a recent study has revealed that lupus nephritis, a rare kidney disease associated with lupus, can suddenly recur even years after…
A recent study published in Arthritis Care & Research illustrated how higher dosages of prednisone lead to better outcomes for lupus nephritis (LN) patients. After one year, participants were found to…
How much should medication cost, and are these treatments cost-effective and accessible for patients? In a press release, biopharmaceutical company Aurinia Pharmaceuticals, Inc. ("Aurinia") shared that an independent review performed…
Evotec SE and Chinook Therapeutics have entered into a strategic partnership in an effort to find, create, and develop viable treatments for those living with chronic kidney diseases. Under the…
The FDA has recently approved of GlaxoSmithKline's (GSK) treatment for lupus nephritis (LN), BENLYSTA. This therapy is the first of its kind, meant to treat systemic lupus and adults with…
by Lauren Taylor from In The Cloud Copy Nephrologists worldwide have shown that there is a huge unmet need when it comes to the treatment of various glomerular diseases, in…
by Danielle Bradshaw from In The Cloud Copy Research that has recently been made available reveals that lupus nephritis - a kind of kidney disease that’s related to lupus -…
Since the company was founded, biotechnology company Kezar Life Sciences ("Kezar") has worked to develop therapies for patients with oncologic and autoimmune disorders. Recently, they highlighted a potential treatment, KZR-616,…
A recent study, published in the journal Medicine, has found that Mycopheenolate mofetil (MMF) could be a more advantageous therapy for lupus nephritis than cyclophosphamide (CYC) when it comes to improving serum complement…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
